Compare PRTA & IBEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTA | IBEX |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.7M | 376.6M |
| IPO Year | 2013 | 2017 |
| Metric | PRTA | IBEX |
|---|---|---|
| Price | $8.15 | $30.86 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 2 |
| Target Price | $19.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 488.0K | 82.2K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.26 |
| EPS | 0.60 | ★ 2.54 |
| Revenue | $814,000.00 | ★ $558,273,000.00 |
| Revenue This Year | $1,111.38 | $14.13 |
| Revenue Next Year | N/A | $5.68 |
| P/E Ratio | $13.75 | ★ $12.17 |
| Revenue Growth | N/A | ★ 9.77 |
| 52 Week Low | $5.52 | $25.94 |
| 52 Week High | $11.80 | $42.99 |
| Indicator | PRTA | IBEX |
|---|---|---|
| Relative Strength Index (RSI) | 33.70 | 51.50 |
| Support Level | N/A | $29.25 |
| Resistance Level | $8.58 | $33.15 |
| Average True Range (ATR) | 0.50 | 1.04 |
| MACD | -0.12 | -0.13 |
| Stochastic Oscillator | 12.65 | 42.54 |
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.